Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama
Investors got to hear Novo Nordisk’s side of the Metsera bidding war drama for the first time on Wednesday, as the company reported third-quarter earnings. A rough quarter underscored the stakes for the Danish pharma.
Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama Read More »
